Marc Tessier-Lavigne, Director at Denali Therapeutics Inc. (DNLI), sold 188,056 shares at $70.35 ($13.2M) on 2021-06-07, disclosed to the SEC on 2021-06-08.
Open-market sale of $13.2M DNLI by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $70.35 | 93,678 | $6.6M | 49.8% |
| 2 | $70.35 | 93,678 | $6.6M | 49.8% |
| 3 | $71.06 | 700 | $50K | 0.4% |
| Total | $70.35 avg | 188,056 | $13.2M | 100% |
| Filing → |
| REGN | SELL | 2022-10-03 | $10.2M | — | Filing → |
| DNLI | SELL | 2022-09-30 | $1.2M | — | Filing → |
| DNLI | SELL | 2022-08-25 | $632K | — | Filing → |